Evidence map›Paper›PMID 35604681›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2022

CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease.

Ning Zhao, Shalini Chopra, Kai Trepka, Yung-Hua Wang, Sasank Sakhamuri, Nima Hooshdaran, Hyunjung Kim, Jie Zhou, Shion A Lim, Kevin K Leung and 13 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Article
  19. Theranostic Targeting of CUB Domain-Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 1 institution in 1 country.

Ning ZhaoDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.ORCID 0000-0003-3699-3369
Shalini ChopraDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
Kai TrepkaDepartment of Medicine, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-8672-6317
Yung-Hua WangDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
Sasank SakhamuriDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.ORCID 0000-0003-1569-2890
Nima HooshdaranDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
Hyunjung KimDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
Jie ZhouDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, California.ORCID 0000-0003-3208-9073
Shion A LimDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, California.
Kevin K LeungDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-2087-4974
Emily A EgusaDepartment of Radiation Oncology, University of California, San Francisco, San Francisco, California.
Jun ZhuDepartment of Radiation Oncology, University of California, San Francisco, San Francisco, California.
Li ZhangDepartment of Medicine, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-3617-2627
Adam FoyeDepartment of Radiation Oncology, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-9910-9836
Renuka SriramDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.ORCID 0000-0003-3505-2479
Emily ChanDepartment of Pathology, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-7290-4004
Youngho SeoDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
Felix Y FengDepartment of Radiation Oncology, University of California, San Francisco, San Francisco, California.
Eric J SmallDepartment of Medicine, University of California, San Francisco, San Francisco, California.
Jonathan ChouDepartment of Medicine, University of California, San Francisco, San Francisco, California.ORCID 0000-0003-1258-0391
James A WellsDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, California.
Rahul AggarwalDepartment of Medicine, University of California, San Francisco, San Francisco, California.
Michael J EvansDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.ORCID 0000-0003-4947-1316
University of California, San Francisco · US

Funding

Medical Scientist Training Program (T32 NRSA Training Grant)T32GM141323 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Aimee Kao · 2021 to 2026
$10.5M
Renewable antibodies to secreted proteins and single and multi-pass cell surfaceP41CA196276 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MARKS, JAMES D. · 2014 to 2018
$5.8M
Precision targeting of T cell cytotoxicity with PETR01CA258297 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AGGARWAL, RAHUL, CRAIK, CHARLES SCOTT · 2021 to 2025
$3.1M
Development of a translational imaging tool as a predictive biomarker for anti-PD-1/PD-L1 immunotherapiesR01EB025207 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI EVANS, MICHAEL JOHN · 2018 to 2021
$2.3M
Affinity-directed tagging of protein binding partners in signalingR01CA191018 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WELLS, JAMES A · 2014 to 2018
$1.6M
MicroPET/CT for Small Animal ImagingS10RR023051 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI VANBROCKLIN, HENRY F. · 2007 to 2007
$1.3M
Combined dual-modality SPECT/CT for small animal imaging research at UCSFS10OD012301 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SEO, YOUNGHO · 2015 to 2015
$1.2M
Regulating Proteolysis to Dissect ApoptosisR01GM097316 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WELLS, JAMES A · 2011 to 2014
$1.1M
NCI NIH HHS P41 CA196276NCI NIH HHS R01 CA191018NCI NIH HHS R01 CA258297NCRR NIH HHS S10 RR023051NIBIB NIH HHS R01 EB025207NIGMS NIH HHS R01 GM097316NIGMS NIH HHS T32 GM141323NIH HHS S10 OD012301
6 · The paper itself

Abstract

purposeWith the improvement in overall survival with 177Lu-PSMA 617, radioligand therapy (RLT) is now a viable option for patients with metastatic castration-resistant prostate cancer (mCRPC). However, responses are variable, in part due to low PSMA expression in 30% of patients. Herein, we evaluated whether the cell surface protein CUB domain-containing protein 1 (CDCP1) can be exploited to treat mCRPC with RLT, including in PSMA-low subsets. EXPERIMENTAL

designCDCP1 levels were evaluated using RNA sequencing from 119 mCRPC biopsies. CDCP1 levels were assessed in 17 post-enzalutamide- or abiraterone-treated mCRPC biopsies, 12 patient-derived xenografts (PDX), and prostate cancer cell lines. 4A06, a recombinant human antibody that targets the CDCP1 ectodomain, was labeled with Zr-89 or Lu-177 and tested in tumor-bearing mice.

resultsCDCP1 expression was observed in 90% of mCRPC biopsies, including small-cell neuroendocrine (SCNC) and adenocarcinomas with low FOLH1 (PSMA) levels. Fifteen of 17 evaluable mCRPC biopsies (85%) demonstrated membranous CDCP1 expression, and 4 of 17 (23%) had higher CDCP1 H-scores compared with PSMA. CDCP1 was expressed in 10 of 12 PDX samples. Bmax values of approximately 22,000, 6,200, and 2,800 fmol/mg were calculated for PC3, DU145, and C4-2B human prostate cancer cells, respectively. 89Zr-4A06 PET detected six human prostate cancer xenografts, including PSMA-low tumors. 177Lu-4A06 significantly suppressed growth of DU145 and C4-2B xenografts.

conclusionsThe data provide the first evidence supporting CDCP1-directed RLT to treat mCRPC. Expanded studies are warranted to determine whether CDCP1 is a viable drug target for patients with mCPRC.

Indexed as

Prostatic Neoplasms, Castration-ResistantRadioisotopesAnimalsAntigens, NeoplasmCell Adhesion MoleculesDipeptidesHeterocyclic Compounds, 1-RingHumansMaleMiceProstate-Specific AntigenRadiopharmaceuticalsTreatment OutcomeZirconiumAntigens, NeoplasmCDCP1 protein, humanCell Adhesion MoleculesDipeptidesHeterocyclic Compounds, 1-RingProstate-Specific AntigenRadioisotopesRadiopharmaceuticalsZirconiumZirconium-89

Identifiers

PMID35604681
PMCPMC9288514
OpenAlexW4282937381

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.